- Previous Close
0.4132 - Open
0.4069 - Bid 0.2807 x 100
- Ask 0.4629 x 100
- Day's Range
0.3500 - 0.4069 - 52 Week Range
0.1900 - 1.7700 - Volume
1,515,926 - Avg. Volume
2,346,932 - Market Cap (intraday)
19.805M - Beta (5Y Monthly) 3.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3100 - Earnings Date May 14, 2025 - May 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
cardiodiagnosticsinc.comRecent News: CDIO
View MorePerformance Overview: CDIO
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDIO
View MoreValuation Measures
Market Cap
19.80M
Enterprise Value
12.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
292.74
Price/Book (mrq)
2.07
Enterprise Value/Revenue
362.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.36%
Return on Equity (ttm)
-133.96%
Revenue (ttm)
34.89k
Net Income Avi to Common (ttm)
-8.38M
Diluted EPS (ttm)
-0.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
7.83M
Total Debt/Equity (mrq)
10.15%
Levered Free Cash Flow (ttm)
-2.41M